NTAP Proposed for C2 in Coronary 'A Win' for Shockwave Medical (SWAV) - Canaccord Genuity
Tweet Send to a Friend
Canaccord Genuity analyst William Plovanic reiterated a Buy rating and $149.00 price target on Shockwave Medical (NASDAQ: SWAV), saying the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE